Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition
Development · 15.04.2026 · 153 (8)
DOI: 10.1242/dev.205259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Development, online erschienen am 21.04.2026. Verfasst von Christina M Piarowski und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-kit, Taste Buds, Protein Kinase Inhibitors, Taste. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Colorado, NIDCD NIH HHS, NIH HHS.
Abstract (Originalsprache)
Taste dysfunction, or dysgeusia, is a common side effect of many cancer drugs. Dysgeusia is often reported by people treated with anti-angiogenic tyrosine kinase inhibitors (TKIs), which inhibit receptor tyrosine kinases (RTKs). However, the mechanisms by which TKIs cause dysgeusia are not understood, as the role of RTKs in adult taste homeostasis is unknown. Here, we find that treating adult mice with the TKI cabozantinib shifts the fate of differentiating functional taste cell subtypes within taste buds. Through behavioral assays, we find this cell fate shift leads to blunted responses to sweet tastants in cabozantinib-treated mice. Finally, we show that inducible knockout of the RTK KIT, which is inhibited by cabozantinib, phenocopies taste cell fate shifts induced by TKI treatment. Our results establish KIT as a regulator of taste cell homeostasis and suggest that KIT inhibition may underlie TKI-induced dysgeusia in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Rocky Mountain Taste and Smell Center, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Immunology, University of Washington, Seattle, WA 98109, USA.
- Developing Scholars Internship Program, Graduate Program in Cell Biology, Stem Cells and Development, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
ORCID-Profile: Elaine T Lam, Jakob von Moltke, Linda A Barlow
Förderung
- University of Colorado
- NIDCD NIH HHS
- NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Piarowski, C. M., Scott, J. K., Wilson, C. E., Lara, H. I., Salcedo, E., Han, A. S., Lam, E. T., Dempsey, P. J., von Moltke, J., & Barlow, L. A. (2026). Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development, 153(8). https://doi.org/10.1242/dev.205259
Vancouver
Piarowski CM, Scott JK, Wilson CE, Lara HI, Salcedo E, Han AS, et al. Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development. 2026;153(8). doi:10.1242/dev.205259
BibTeX
@article{Piarowski2026,
author = {Piarowski, Christina M and Scott, Jennifer K and Wilson, Courtney E and Lara, Heber I and Salcedo, Ernesto and Han, Andrew S and Lam, Elaine T and Dempsey, Peter J and von Moltke, Jakob and Barlow, Linda A},
title = {Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition},
journal = {Development},
year = {2026},
volume = {153},
number = {8},
doi = {10.1242/dev.205259}
}
EUVIMED